Lisata Therapeutics (LSTA) Q1 2026 earnings summary

Executive summary

• Focused on developing certepetide, a novel agent to enhance delivery of anti-cancer drugs in solid tumors, with ongoing and completed Phase 2 trials in multiple indications including pancreatic cancer.

• Recent clinical data show promising efficacy and safety for certepetide in combination with standard-of-care therapies, with ongoing investigator-initiated trials in glioblastoma, pancreatic, colon, and appendiceal cancers.

• Entered into a merger agreement with Kuva Labs Inc., with a proposed acquisition involving a $5.00 per share cash offer plus a $1.00 contingent value right, subject to regulatory and shareholder approval.

• Terminated exclusive license with Qilu Pharmaceutical for Greater China, reverting all rights to certepetide back to the company.

Financial highlights

• Net loss for Q1 2026 was $4.5 million, compared to $4.7 million in Q1 2025.

• Operating expenses decreased 15.5% year-over-year to $4.9 million, driven by a 53.7% reduction in R&D expenses due to completion of the Bolster trial and staff reductions.

• General and administrative expenses increased by $0.5 million, mainly due to legal and consulting costs related to the proposed acquisition.

• Cash and cash equivalents were $13.1 million as of March 31, 2026, with working capital of $10.7 million and stockholders' equity of $10.9 million.

• No revenue recognized in Q1 2026; no milestone or royalty revenue received.

Outlook and guidance

• Management has substantial doubt about the ability to continue as a going concern for the next twelve months without additional funding.

• Short-term capital management includes delaying certain readiness activities for a planned Phase 3 study in metastatic pancreatic cancer.

• Actively seeking additional funding through equity, debt, collaborations, or licensing; may reduce spending further if needed.